Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
We performed a retrospective analysis of 101 impotent patients using intracavernous self-injections as primary therapy for vasculogenic impotence. A total of 70 patients used an average of 5.58 micrograms prostaglandin E1 (95% confidence interval 4.83 to 6.34 micrograms) as a single agent, and 31 injected 0.40 ml. (95% confidence interval 0.342 to 0.457 ml.) of a combination of papaverine (12 mg./ml.), phentolamine (1 mg./ml.) and prostaglandin E1 (9 micrograms/ml.). We describe the procedure to establish the dosage for home use and discuss the implications of the low dosages relative to previous reports.
von Heyden
B
B
Department of Urology, University of California School of Medicine, San Francisco.
Donatucci
C F
CF
Kaula
N
N
Lue
T F
TF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000527:Alprostadil / Q000008:administration & dosage* / Q000627:therapeutic use; D001158:Arteries / Q000187:drug effects / Q000503:physiopathology; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage* / Q000627:therapeutic use; D010410:Penile Erection / Q000187:drug effects*; D010413:Penis / Q000098:blood supply*; D010646:Phentolamine / Q000008:administration & dosage* / Q000627:therapeutic use; D012189:Retrospective Studies; D012646:Self Administration
D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine